PURPOSE: To describe the characteristics of new users of @entity1924 in Europe with the aim to support the evaluation of its benefit/risk as used in regular clinical practice before the implementation of labeling changes recommended by the European Medicines Agency. METHODS: New users of @entity1924 were identified in populations enrolled in five European health automated databases in the UK ( @entity283 [ @entity283 ]), Spain (EpiChron cohort and Information System for the Improvement of Research in Primary Care [SIDIAP]), Sweden (National Registers), and Germany (German Pharmacoepidemiological Research Database [GePaRD]) between 2002 and 2012. New users were characterized according to the prevalence of @entity65 and other comorbidities, concurrent use of interacting medications, new contraindications, duration of use, and potential off-label prescribing. RESULTS: We identified 22  593 new users of @entity1924 . The median age was between 68.0 ( @entity283 ) and 73.7 (Sweden) years. More than 78% of users had concomitant @entity65 , and between 78.8% (GePaRD) and 91.6% ( @entity283 ) were treated with interacting medications. Prevalence of new cardiovascular contraindications ranged from 1.5% ( @entity283 ) to 11.6% (GePaRD), and concurrent use of two or more antiplatelet drugs ranged from 6.3% (SIDIAP) to 13.5% (EpiChron cohort). Between 39.4% (Sweden) and 52.9% ( @entity283 ) of users discontinued @entity1924 in the first 3  months. Between 41.0% (SIDIAP) and 93.4% ( @entity283 ) were considered to have received @entity1924 according to the European Medicines Agency labeling. CONCLUSIONS: In this collaborative European study, most @entity1924 users were elderly @entity1 with a high prevalence of @entity65 and other comorbidity and concurrent use of interacting drugs, indicating that this is a vulnerable population at high risk of complications, especially cardiovascular events.    2017 The Authors. Pharmacoepidemiology and Drug Safety Published by John Wiley _ Sons Ltd.

Characterization of new users of XXXX in the UK, Spain, Sweden, and Germany.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease', 'cardiovascular diseases'] @entity283 :: ('OMIM:603663', 'Disease') :: ['THIN', 'The Health Improvement Network'] @entity1924 :: ('MESH:C045645', 'Chemical') :: ['cilostazol']
@entity1924 :: (MESH:C045645,Chemical) :: ['cilostazol']
